As mentioned, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals) appear to have already filed an infringement notice. From their company announcement on August 7:
"In addition, for a number of our products (including Apriso®, Cardizem®, Onexton®, Uceris®, Relistor®, Jublia® and Xifaxan® in the U.S. and Wellbutrin® XL and Glumetza® in Canada), we have commenced (or anticipate commencing) infringement proceedings against potential generic competitors in the U.S. and Canada. If we are not successful in these proceedings, we may face increased generic competition for these products."
"The Company continues to believe that the Jublia® related patent is valid and enforceable and on August 7, 2018 an appeal of this decision was filed."
As for why did the price rise this week? Who knows. Perhaps because it remains fundamentally undervalued and 'up' would be the rational direction? Keeping in mind, markets aren't always rational and next week it could be down or sideways.
Add to My Watchlist
What is My Watchlist?
